Updated:
Nkarta
Nkarta, led by CEO Paul Hastings, develops off-the-shelf NK cell therapies and has advanced four clinical programs since its 2015 founding.
Nkarta
Nkarta launched in 2015 within the South San Francisco biotechnology corridor, co-founded by Dario Campana and backed by early institutional crossover investors including RA Capital Management and Samsara BioCapital. The firm closed a $240 million crossover Series C in May 2020, converting it to a public listing via an upsized IPO on Nasdaq in July 2020—an unusually rapid path from startup to public markets even within biotech's compressed timelines. The firm's platform engineers donor-derived natural killer cells with a membrane-bound IL-15 to enhance persistence without exogenous cytokine support, targeting cancer and autoimmune indications through CAR-mediated recognition. The lead asset, NKX101, completed Phase 1 evaluation in relapsed/refractory acute myeloid leukemia; a follow-on program, NKX019, advanced into a Phase 1 trial for non-Hodgkin lymphoma and, in an October 2023 strategic shift, became the centerpiece of Nkarta's push into lupus nephritis—an autoimmune expansion that mirrors the broader field migration of CAR-T developers seeking larger addressable markets. Nkarta operates a 130,000-square-foot in-house GMP manufacturing facility in South San Francisco, a capital-intensive vertical integration atypical for a clinical-stage biotech. Co-founder Dario Campana, a former St. Jude Children's Research Hospital investigator, contributed foundational intellectual property that the company licensed into its platform. The board includes Samsara BioCapital's Srini Akkaraju and RA Capital's Peter Kolchinsky as non-executive directors. An October 2024 research collaboration with Lupus Research Alliance marked the firm's most visible clinical community engagement since the autoimmune pivot, placing NKX019 in an open-label basket study with academic centers evaluating kidney outcomes in lupus nephritis patients. Nkarta owns and operates its internal GMP manufacturing infrastructure—a structural differentiator in the NK cell therapy space where most clinical-stage competitors outsource to contract manufacturers. This captive capacity gives the firm direct control over cycle times and cost of goods, but concentrates operational risk and capital intensity in an asset class where clinical proof-of-concept remains the sector's unresolved gatekeeper.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
South San Francisco, CA, United States
Principals
Paul Hastings
Chief Executive Officer
Sector focus
Frequently asked questions
What is Nkarta's core therapeutic approach and how does it differ from CAR-T cell therapy?
Nkarta engineers natural killer (NK) cells sourced from healthy donors with chimeric antigen receptors (CARs) and a membrane-bound form of IL-15 for persistence. Unlike autologous CAR-T therapies—which require patient-specific manufacturing and carry significant risk of cytokine release syndrome—Nkarta's allogeneic NK cells are designed as an off-the-shelf product that can be dosed without HLA matching and with a more favorable safety profile. The firm currently targets both hematologic malignancies and autoimmune disease with this platform.
Why did Nkarta pivot into autoimmune disease, and which program leads that effort?
In late 2023, Nkarta strategically expanded NKX019 into autoimmune indications, starting with lupus nephritis, following preclinical evidence that CD19-directed NK cells can deplete pathogenic B cells. The autoimmune pivot mirrors moves by CAR-T developers like Cabaletta Bio and Kyverna Therapeutics, but applies a non-T-cell, allogeneic modality. The decision was accompanied by a clinical hold on earlier AML work for NKX101 as the firm concentrated resources around NKX019.
Who holds the key intellectual property behind Nkarta's NK cell engineering platform?
Nkarta's foundational IP traces to co-founder Dario Campana, a cell therapy researcher who previously held a faculty position at St. Jude Children's Research Hospital and later the National University of Singapore. Campana's work on membrane-bound IL-15 and CAR-expressing NK cells forms the scientific backbone of the firm's platform, which Nkarta licensed at founding and supplemented with internal engineering for clinical-scale manufacturing.
Does Nkarta use contract manufacturing organizations, or does it produce its own cell therapies?
Nkarta built and operates a 130,000-square-foot current Good Manufacturing Practice (cGMP) facility at its South San Francisco headquarters. This internal manufacturing capacity is atypical for a clinical-stage cell therapy biotech and gives the firm direct oversight of production quality, supply chain logistics, and cost structure—a deliberate capital allocation decision that signals intent to commercialize without relying on external CDMOs.
Who runs Nkarta's day-to-day operations and investment strategy?
Paul Hastings has served as Chief Executive Officer since 2015, guiding Nkarta from seed-stage startup through its 2020 Nasdaq IPO. As a public company, Nkarta's operational and capital-allocation decisions are overseen by a board that includes representatives from its largest crossover investors—specifically Samsara BioCapital's Srini Akkaraju and RA Capital Management's Peter Kolchinsky—reflecting typical biotech venture governance where early financial sponsors maintain board seats post-listing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: